Jeffrey A. Allen, MD

University of Minnesota
BIO

Dr. Jeffrey Allen is a neuromuscular specialist and clinical investigator at the University of Minnesota in Minneapolis. After completion of his residency training at Tufts University and fellowship in neuromuscular medicine at Harvard Medical School, Dr. Allen joined the faculty at Northwestern University in Chicago. In 2014 he moved to the University of Minnesota, but still holds an adjunct appointment at Northwestern and continues to see patients with inflammatory neuropathy in Chicago on a limited basis. In Minnesota Dr. Allen attends a dynamic neuromuscular clinic, with a clinical focus on peripheral neuropathy, myasthenia gravis, and muscle disorders. He has a particular interest in acquired inflammatory neuropathies, and recently successfully speared an effort to have the University of Minnesota named as a certified Center of Excellence by the GBS/CIDP International Foundation. Dr. Allen’s research efforts have focused on improving the diagnosis and treatment of patients with inflammatory neuropathy.
VIDEO & RESOURCES

  • 12:30
    Improving CIDP Diagnosis: The Challenges of Under and Over Diagnosis
    Understand the challenges associated with accurately diagnosing CIDP
  • 12:50
    Optimizing IgG Therapy in Chronic Autoimmune Neuropathies
    Review options for individualizing treatment and tools used to assess IgG performance
  • 03:32
    CIDP Assessment Tools: INCAT
    Learn about the The INCAT scores and variations of them used to evaluate outcome measures for immune-mediated neuropathies
  • 01:52
    CIDP Assessment Tools: Grip Strength
    Listen to a discussion about Discussing tools that are commonly used to measure grip strength in CIDP
  • 02:15
    CIDP Assessment Tools: Rasch Overall Disability Score
    Hear a brief description of the Rasch version of the Overall Disability Score used in CIDP diagnosis and treatment
  • 02:11
    CIDP Assessment Tools: Medical Research Council Sum Score
    Understand how the Medical Research Council (MRC) Sum Score can be used for evaluating muscle strength in CIDP
Mel Berger, MD, PhD
Mel Berger, MD, PhD

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring
BIO

Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland. He completed his internship and residency in pediatrics at Boston Children’s Hospital. He did an allergy-clinical immunology fellowship at NIH, and is Board Certified in Pediatrics and Allergy-Immunology. He served as Assistant Chief of Allergy-Immunology at Walter Reed Army Medical Center and had an initial faculty appointment at the Uniformed Services University of Health Sciences.

In 1984, he returned to Cleveland and joined the faculty of Case Western Reserve as Chief of the Division of Allergy-Immunology at Rainbow, Babies and Children’s Hospital and he rose to Professor of Pediatrics, Pathology and General Medical Sciences (Oncology). In 2008, Dr. Berger joined CSL Behring, but he continues to hold a faculty appointment at Case. He served for more than 20 years in the US Army and Army Reserve, including commanding a hospital unit during the peace effort in former Yugoslavia, and retired from the Army as a Colonel.

Dr. Berger's research has focused on control of inflammatory responses and on antigen-antibody and complement interactions, particularly in primary immune deficiency diseases and cystic fibrosis. He has been a leader in research on the clinical use of immunoglobulins and played a key role in developing the use of portable pumps to give IgG subcutaneously. He has published more than 100 peer-reviewed papers on his research, as well as numerous chapters and review articles.

Dr. Berger is a Fellow of the American Academy of Allergy Asthma and Immunology, the American Pediatric Society, and the American Academy of Pediatrics. He has been elected to the American Society for Clinical Investigation and the Society for Pediatric Research, and has served as a Director of the American Board of Allergy and Immunology and on numerous FDA and NIH panels.

VIDEO & RESOURCES

  • 8:25
    Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy

    Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.

Vera Bril, BSc, FRCPC, MD
Vera Bril, BSc, FRCPC, MD

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada
BIO

Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology. She has particular expertise in the diagnosis and management of patients with complex neuromuscular disorders. Her research interests have centered on the diagnosis and evidence-based treatment of myasthenia gravis, inflammatory polyneuropathies, and diabetic sensorimotor polyneuropathy. Her work has helped set the standards for electrophysiological investigations in the definition and evaluation of the progression of chronic polyneuropathies. Her research has helped establish the role of intravenous immunoglobulin in the treatment of myasthenia gravis and the Guillain-Barré Syndrome, and the long-term treatment of chronic inflammatory demyelinating polyneuropathy.

She has acted in an advisory capacity to Health Canada and the FDA. Dr Bril also serves as the Deputy Physician-in-Chief for Economic Affairs for the Department of Medicine at the University Health Network and Mount Sinai Hospital and Chair of the Economics committee. She is part of the Department of Medicine Executive Committee and helps administer this group of 300 physicians.

VIDEO & RESOURCES

  • 5:24
    Overview and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    Learn more about the mechanism of action, symptoms, diagnosis, and treatment of CIDP.

David R. Cornblath, MD
David R. Cornblath, MD

David R. Cornblath, MD

Johns Hopkins University, Baltimore, MD, USA
BIO

David R. Cornblath received his MD from Case Western Reserve University and completed his residency and fellowship at the Hospital of the University of Pennsylvania under Prof. A.K. Asbury. He is Professor of Neurology at Johns Hopkins University and Director of the Neurology EMG Laboratory at the Johns Hopkins Hospital. His clinical and research interests are peripheral neuropathies.

Prof. Cornblath has co-authored a book entitled Diagnosis and Management of Peripheral Nerve Disorders and written over 200 articles and chapters. He is Editor-in-Chief of the Journal of the Peripheral Nervous System, Secretary/ Treasurer of the Peripheral Nerve Society, a member of the Board of Directors of the GBS/CIDP Foundation International and the Foundation for Peripheral Neuropathy, and Chair of one of the Hopkins Institutional Review Boards.

VIDEO & RESOURCES

  • 7:23
    Overview and Treatment of Guillain-Barré Syndrome (GBS)

    Learn more about the features, symptoms, diagnosis, and treatment of GBS.

Peter Donofrio, MD
Peter Donofrio, MD

Peter Donofrio, MD

Vanderbilt University Medical Center, Nashville, TN, USA
BIO

Peter D. Donofrio, M.D. is a Professor of Neurology at Vanderbilt University Medical Center. He is a graduate of The Ohio State University School of Medicine and pursued a residency in neurology and a neuromuscular fellowship at the University of Michigan. Dr. Donofrio is board certified in Neurology, Internal Medicine, EMG and Neuromuscular Disorders. He is Chief of the Neuromuscular Section and Director of the EMG lab at Vanderbilt.

Other duties include Directorship of the MDA Clinic and the ALS Clinic. He is a member of the Medical Advisory Committee of the GBS/CIDP International Foundation; Vanderbilt University Medical Center is a certified Center of Excellence for the GBS/CIDP International Foundation. Dr. Donofrio has a special interest in all types of peripheral neuropathies, particularly GBS and CIDP, but also cares for many patients with myasthenia gravis, ALS, and muscle disorders. He is the author of the textbook entitled The Textbook of Peripheral Neuropathy published in April 2012 by Demos Medical.

VIDEO & RESOURCES

  • 25:18
    Incidence of GBS and CIDP Following Influenza Vaccination

    Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

Karissa Gable, MD
Karissa Gable, MD

Karissa Gable, MD

Duke University Medical Center in Durham, North Carolina
BIO

Dr. Karissa Gable is a Neuromuscular specialist at Duke University Medical Center in Durham, North Carolina. She is a graduate of the University of North Carolina at Chapel Hill School of Medicine and pursued a residency in Neurology at Northwestern University and a Neuromuscular fellowship at Harvard Medical School. Dr. Gable is board certified in Neurology, Electrodiagnostic Medicine and Neuromuscular Disorders.

Dr. Gable has a special interest in all types of peripheral neuropathies, particularly GBS and CIDP, but also cares for many patients with myasthenia gravis and muscle disorders. Other duties include Directorship of the Neuromuscular Fellowship Program at Duke University.

VIDEO & RESOURCES

  • 09:29
    Fatigue in CIDP
    Engage in a presentation on the comparison between active and remission disease states in CIDP.
Kenneth C. Gorson, M.D.
Kenneth C. Gorson, M.D.

Kenneth C. Gorson, M.D.

Tufts University School of Medicine
BIO

Kenneth C. Gorson, M.D. is a Professor of Neurology in the Department of Neurology at St. Elizabeth’s Medical Center, Tufts University School of Medicine, in Boston. Dr. Gorson has published over 90 original peer-reviewed research articles, book chapters, and reviews pertaining to Guillain-Barre´ syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), paraprotein associated neuropathies, vasculitic neuropathy, and various other inflammatory and immune-mediated disorders of the peripheral nervous system. His clinical and research expertise extends to patients with neuropathies associated with diabetes, connective tissue disorders, and cancer, inherited peripheral neuropathies, and disorders of muscle, myasthenia gravis, and amyotrophic lateral sclerosis. Professor Gorson also has extensive expertise in the medical management of numerous chronic neuropathic and musculoskeletal pain disorders. He has been a principal investigator in several clinical research studies, including experimental treatment trials for CIDP, multifocal motor neuropathy, myasthenia gravis, diabetic neuropathy, painful neuropathies, and post-herpetic neuralgia. He has lectured widely to medical specialists and patient support groups on various topics in the field of neuromuscular diseases.

Dr. Gorson is the Chairman of the Global Medical Advisor Board for the GBS/CIDP Foundation international, the United States Principal Investigator and country coordinator for the International Guillain-Barre Outcome Study (IGOS) and also serves on the Steering Committee for IGOS, Secretary for the Inflammatory Neuropathy Consortium, serves on the editorial board for Muscle & Nerve, and is an active member of the American Academy of Neurology (AAN), American Association of Electrodiagnostic Medicine, and Peripheral Nerve Society, and has previously served on the sub-committee responsible for the selection of neuromuscular courses for the annual meeting of the Academy. He also served as a Councilor for the Neuromuscular Section for the AAN.

In his teaching capacity, Dr. Gorson has served as Director of the Tufts Neurology Residency Training Program and was responsible for resident candidate selection, and supervises the daily academic activities of the Neurology resident trainees. He is also an integral part of the teaching staff for the neurology and medical interns and residents at St. Elizabeth’s Medical Center and medical students from Tufts University School of Medicine.

VIDEO & RESOURCES

  • 19:15
    GBS and Zika Virus
    Understand the latest information on the Zika Virus and its relationship to Guillain-Barre´ syndrome
Jonathan S. Katz, MD
Jonathan S. Katz, MD

Jonathan S. Katz, MD

Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California
BIO

Jonathan S. Katz, MD, is the Director, Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California. He received his BA from The Johns Hopkins University and his medical degree from Tulane University School of Medicine. He subsequently completed his neurology training at the University of Washington and neuromuscular diseases at the University of Texas, Southwestern Medical Center.

Dr. Katz is board certified in in Psychiatry and Neurology and specializes in the management and treatment of neuromuscular diseases such as CIDP, GBS, ALS, myasthenia gravis and multifocal motor neuropathy. He also sits on the medical advisory board of the Guillain-Barre CIDP Foundation International, California State Myasthenia Gravis Association and Myasthenia Gravis Association of America. He has authored over 80 publications, written 7 text book chapters and has participated in more than 23 Investigator Initiated Studies over the past 10 years, and has been national PI in several ALS trials. Notably among his many contributions, Dr. Katz has been the first author of several pioneering clinical papers that have focused on novel presentations which have become part of the neurological nomenclature including distal acquired demyelinating sensory polyneuorpathy (DADS), isolated neck extensor myopathy (INEM), multifocal acquired motor axonopathy (MAMA), and brachial amyotrophic diplegia (BAD).

VIDEO & RESOURCES

  • 09:15
    Electrophysiologic Findings In Multifocal Motor Neuropathy
    Explore electrophysiologic findings of MMN in addition to the classical electrophysiological conduction block
  • 09:51
    Global Multifocal Motor Neuropathy Quality of Life Patient Survey
    Examine a quality of life patient study that identifies needs in education and treatment for patients with MMN.
Hans D. Katzberg, MD, MSc, FRCP(C)
Hans D. Katzberg, MD, MSc, FRCP(C)

Hans D. Katzberg, MD, MSc, FRCP(C)

University Health Network /Toronto General Hospital Canada
BIO

Dr. Hans Katzberg is a neuromuscular specialist and clinical investigator at the University Health Network / Toronto General Hospital and has been on faculty at the University of Toronto as Assistant Professor of Neurology. He obtained his undergraduate and medical degrees at the University of British Columbia and did his residency in neurology at the University of Toronto where he was chief resident from 2006-7. He later completed fellowships in neuromuscular medicine and neurophysiology (EMG) at Stanford University, where he also obtained a Master’s degree in clinical epidemiology.

He has been on staff at the Ellen and Martin Prosserman Center for Neuromuscular Diseases at TGH since 2010, where he runs neuromuscular and EMG clinics, is active in training of neurology and physiatry residents / fellows and conducts clinical research. He is cross-appointed to Sick Kids Hospital where he coordinates a transition clinic for young adults with neuromuscular conditions. In 2014 he took over as fellowship program director at the University of Toronto for the Division of Neurology. He is Associate Editor for the Canadian Journal of Neurological Science and co-chair for research in the Canadian Neuromuscular Disease Network. He has a research focus in outcome measures and clinical trials in immune mediated neuromuscular junction disorders such as myasthenia gravis and neuropathies such as CIDP.

VIDEO & RESOURCES

  • 10:39
    SCIg in Multifocal Motor Neuropathy

    Hear the results of a trial to determine the feasibility of switching patients with multifocal motor neuropathy on intravenous to subcutaneous immunoglobulin.

Richard A. Lewis, MD
Richard A. Lewis, MD

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA
BIO

Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program. He is Director of the GBS-CIDP Foundation Center of Excellence at Cedars-Sinai. Prior to his move to California in 2013, he was Associate Chair of Neurology at Wayne State University where he had been for 19 years.

He has been on the Board of Directors of the Peripheral Nerve Society, and on the Steering Committee of the Inflammatory Neuropathy Consortium. He is on the Medical Advisory Boards of the GBS-CIDP Foundation and the Myasthenia Gravis Foundation. He has been involved as an investigator, steering committee member and DSMB member in clinical trials in a number of immune mediated disorders including CIDP, myasthenia gravis and multifocal motor neuropathy.

VIDEO & RESOURCES

  • 13:53
    Pathogenesis and Mechanism of Action of Inflammatory Neuropathies

    Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

Michael Lunn, PhD
Michael Lunn, PhD

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

BIO

Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery. He trained in medicine at Emmanuel College, Cambridge and the Charing Cross and Westminster Hospitals Medical School. He worked at the Royal Brompton and Hammersmith Hospitals before receiving his specialist neurology training in the UK at Guy’s, King’s, St Thomas’ and Charing Cross Hospitals, Hurstwood Park Neurosciences Centre and Queen Square, and at the Johns Hopkins Hospital in Baltimore, USA. He was appointed to a Consultant position at NHNN in 2005.

VIDEO & RESOURCES

  • 14:01
    Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

    Learn how an algorithm could be used to personalize dosing schedules for IVIg.

Orell Mielke, MD
Orell Mielke, MD

Orell Mielke, MD

Global Clinical Research and Development, CSL Behring
BIO

Orell Mielke is a board certified neurologist who completed his medical training at the University of Heidelberg and partly in Chelmsford, London and Porto Alegre, Brasil. He was trained in Neurology and Psychiatry at the University Hospital of Mannheim. Before moving to the pharmaceutical industry, he spent 14 months at the Cochrane Stroke Center at the Western General Hospital in Edinburgh, Scotland and authored several systematic reviews in the field of acute ischemic stroke.

He gained over 11 years of industry experience at the CRO Parexel, at the Biotechnical Company Biotest and a Plasma Company Biotest before moving to CSL Behring in 2011 where he leads the clinical development of Immunoglobulins in neurological and immunological indications in the function of a Global Program Director. He has authored and co-authored several neurological publications and is a member of the German Society of Neurologists.

VIDEO & RESOURCES

  • 2:16
    Time to Response for Immunoglobulins in the Treatment of CIDP

    Understand the time variations in response to IVIg therapy during the CIDP PRIMA Trial.

Nabil Moumane, MD
Nabil Moumane, MD

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring
BIO

Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring. He completed his medical training at the University of Casablanca in Morocco. He also has a Master of Biomedical and Physical Engineering of Health in the University of Saints-Pères, Paris, and Biostatistics for the Health and Biological Sciences in Pierre at Marie Curie University in Paris. Before joining the pharmaceutical industry he spent 3 years in Emergency department. He gained over 10 years of industry experience in Medical Affairs departments first in central nervous system and psychiatry and then, from 2010 he joined CSL Behring as a medical manager in immunology.

VIDEO & RESOURCES

  • 3:00
    Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

    Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

Zaeem A. Siddiqi, MD, PhD
Zaeem A. Siddiqi, MD, PhD

Zaeem A. Siddiqi, MD, PhD

University of Alberta, Edmonton, Alberta, Canada
BIO

Dr. Zaeem Siddiqi, MD, PhD is an Associate Professor of Medicine (Neurology) at the University of Alberta and Director of the neuromuscular program. He specializes in the diagnosis and management of patients with complex neuromuscular and autonomic disorders. As an expert in electrodiagnosis of neuromuscular disorders he has regularly conducted physician-training workshops for Canadian Congress of Neurosciences, American Academy of Neurology, and American Association of Neuromuscular Diseases and Electrodiagnostic Medicine (AANEM).

He is involved in translational and clinical research in myasthenia gravis and has been the lead investigator in several national and international clinical trials in this disease. His work has optimized the use of intravenous immunoglobulin in various neuromuscular diseases in the rural regions of Northern Alberta and neighbouring provinces. Dr. Siddiqi has also served in an advisory capacity to Health Canada and chairs the News Science Editorial Board committee for the AANEM.

VIDEO & RESOURCES

  • 7:20
    Subcutaneous Immunoglobulin: Feasibility and Safety in Neuromuscular Diseases

    Learn how subcutaneous immunoglobulin provides the additional benefit of flexibility of home infusion in patients with neuromuscular disease.

Claudia Sommer, MD
Claudia Sommer, MD

Claudia Sommer, MD

University of Würzburg, Würzburg, Germany
BIO

Claudia Sommer is a Professor of Neurology at the University of Würzburg, Germany. She received training in psychiatry, neuropathology, experimental anesthesia, and neurology. At the University of Würzburg she serves as a consultant in neurology, organizes an outpatient clinic for patients with pain, and leads the Peripheral Nerve Laboratory. Professor Sommer’s research interests include: the role of cytokines in the pathophysiology of pain, improvement and standardization of diagnostics in neuropathies, and the pathophysiology of antibody-mediated diseases. She has written more than 150 original research papers and more than 100 reviews and book chapters, and has edited several books.

Professor Sommer is active in the development of national and international guidelines on treatment of peripheral neuropathies, nerve and skin biopsies, and treatment of fibromyalgia and neuropathic and facial pain. She is a reviewer for scientific journals and the German Research Foundation (DFG), and serves on the editorial boards of several scientific journals.

VIDEO & RESOURCES

  • 9:35
    Clinical Studies for the Treatment of CIDP with Immunoglobulin

    Discover the results of two recent clinical studies of IVIg treatments for CIDP.

  • 12:34
    Overview and Treatment of Multifocal Motor Neuropathy
    Learn about the diagnosis and treatment of multifocal motor neuropathy
Back to Top